Nuzenio

Psoriasis Study

Psoriasis Study news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLiveHCPLive · Fri, 07 Aug 2026 23:10:36 GMTOral TYK2 Inhibitor Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Trial - Dermatology TimesDermatology Times · Fri, 07 Aug 2026 16:04:43 GMTOnychoscopy in Nail Psoriasis: A Narrative Review of Diagnostic Utility, Disease Severity Assessment, Musculoskeletal Associations, and Treatment Monitoring - cureus.comcureus.com · Tue, 04 Aug 2026 06:06:23 GMTSurprising Drug Targets for Psoriasis Emerge From Comprehensive CRISPR Study of Human Skin Cells | Newswise - newswise.comnewswise.com · Mon, 03 Aug 2026 14:45:00 GMTGuselkumab shows no TB safety signal over five years in psoriatic disease, study finds - Hospital Healthcare EuropeHospital Healthcare Europe · Thu, 30 Jul 2026 07:00:00 GMTInnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study - GlobeNewswireGlobeNewswire · Mon, 27 Jul 2026 10:50:10 GMT

Timeline

Fri, 07 Aug 2026 23:10:36 GMTSocrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLive
Fri, 07 Aug 2026 16:04:43 GMTOral TYK2 Inhibitor Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Trial - Dermatology Times
Tue, 04 Aug 2026 06:06:23 GMTOnychoscopy in Nail Psoriasis: A Narrative Review of Diagnostic Utility, Disease Severity Assessment, Musculoskeletal Associations, and Treatment Monitoring - cureus.com
Mon, 03 Aug 2026 14:45:00 GMTSurprising Drug Targets for Psoriasis Emerge From Comprehensive CRISPR Study of Human Skin Cells | Newswise - newswise.com
Thu, 30 Jul 2026 07:00:00 GMTGuselkumab shows no TB safety signal over five years in psoriatic disease, study finds - Hospital Healthcare Europe
Mon, 27 Jul 2026 10:50:10 GMTInnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study - GlobeNewswire

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Psoriasis Study.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.